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Abstract
Background: Endothelial-Monocyte Activating Polypeptide (EMAP II) is a secreted protein with well-established anti-
angiogenic activities. Intracellular EMAP II expression is increased during fetal development at epithelial/mesenchymal
boundaries and in pathophysiologic fibroproliferative cells of bronchopulmonary dysplasia, emphysema, and scar fibroblast
tissue following myocardial ischemia. Precise function and regulation of intracellular EMAP II, however, has not been
explored to date.
Methodology/Principal Findings: Here we show that high intracellular EMAP II suppresses cellular proliferation by slowing
progression through the G2M cell cycle transition in epithelium and fibroblast. Furthermore, EMAP II binds to and is
phosphorylated by Cdk1, and exhibits nuclear/cytoplasmic partitioning, with only nuclear EMAP II being phosphorylated.
We observed that extracellular secreted EMAP II induces endothelial cell apoptosis, where as excess intracellular EMAP II
facilitates epithelial and fibroblast cells migration.
Conclusions/Significance: Our findings suggest that EMAP II has specific intracellular effects, and that this intracellular
function appears to antagonize its extracellular anti-angiogenic effects during fetal development and pulmonary disease
progression.
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Introduction
Endothelial Monocyte Activating Polypeptide II (EMAP II, also
known as AIMP-1, Scye-1, and p43), a single chain polypeptide
protein originally isolated from a murine fibrosarcoma, is
ubiquitously expressed as a 34-kDa intracellular protein [1]. On
the cell surface, it undergoes proteolytic cleavage [2,3] to generate
a <22-kDa C-terminal peptide [4,5,6] that functions as a potent
anti-angiogenic protein [1,7]. As an extracellular molecule, C-
terminal EMAP II (ct-EMAP II) is known to activate endothelial
cells, neutrophils and mononuclear phagocytes [5,6]; consequent-
ly, ct-EMAP II has shown the capacity to prime tumor vasculature
for a locally destructive process, or to be anti-angiogenic in its own
capacity [1,8,9,10]. Mechanistically ct-EMAP II suppresses
primary and metastatic tumor growth through inhibition of
endothelial cell adhesion to fibronectin [11], disrupts alveolar
epithelial type II to type I cell transdifferentiation [12], regulates
pulmonary cell-cell cohesion, aggregation, and lung assembly [13],
blockade of fibronectin matrix assembly via a5b1 integrin [9,11],
and interference with vascular endothelial growth factor (VEGF)
induced pro-angiogenic signaling [14].
Based on a high degree of homology between EMAP II and the
aminoacyl-tRNA synthetase (ARS) p43, EMAP II is considered a
member of the larger ARS family [15]. ARSs are proteins that
catalyze ligation of their cognate amino acids to specific tRNAs.
Although the basic core domain is well conserved among the
ARSs, N- or C- terminal residues on p43 suggest that it is likely to
mediate additional functions beyond amino acid loading of
tRNAs. P43 is one of three auxiliary proteins (p38, p18, and
p43), with p38 having a pivotal role in the assembly of the subunits
of the eukaryotic tRNA synthetase complex [16]. Interestingly, the
extracellular function of p43 is similar to EMAP II in that it
possesses extracellular anti-angiogenic activities [17], while its
intracellular role beyond that of an RNA binding protein remains
less well understood [18].
Here, we examine the intracellular role for EMAP II.
Previously, we and others have found high levels of EMAP II at
epithelial/mesenchymal cell interfaces of proliferating and differ-
entiating cells in embryonic lungs [19,20,21], within dysplastic
fibroproliferative regions of bronchopulmonary dysplasia (BPD)
[22] and in emphysematous lungs [23], suggesting that EMAP II
might regulate cell proliferation in organ development and disease.
We demonstrate that overexpression of intracellular EMAP II
delays cellular proliferation and progression through the G2M
phase of cell cycle. Furthermore, EMAP II expression increases
during the cell cycle at the S and G2M phases, leading to its
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33101phosphorylation. Intracellular EMAP II exhibits distinct nuclear/
cytoplasmic partitioning and associates with Cdk1 in the N-
terminal region. In conjunction with the delay in cell cycle and
reduced proliferation, there is a marked increase in cellular
motility. These studies indicate that EMAP II possesses an
intracellular role that may influence cellular proliferation and
migration during fetal development and in pulmonary disease
progression.
Results
Overexpression of EMAP II reduces cell proliferation and
delays G2M exit in cell cycle
To determine the role of intracellular EMAP II in proliferating
cell populations, stable clonal A549 cell populations that
overexpressed EMAP II protein (pFEII-GFP) or an empty vector
(pEGFP-N3) were established using antibiotic pressure selection
(WB of whole cell lysate, Figure 1A and 1B). Overexpression of
EMAP II delayed cell doubling times (Figure 1C, p,0.05,
ANOVA, representative experiment, n=6, performed on 3
different occasions) and growth rate (Figure 1D, WST-1,
p,0.001, ANOVA, representative experiment, n=4 (in triplicate),
performed on 4 different occasions) as compared to an empty
vector control. Delays in doubling time and growth rate were not
due to induction of apoptosis as there were no differences between
apoptosis-related proteins in form of PARP-1 cleavage and
phospho-JNK cellular protein as measured by WB or detection
of early apoptosis and annexin/PI via FACs analysis (data not
shown) between the two clonal cell populations. As EMAP II’s
ability to reduce proliferation and doubling times was not
secondary to apoptosis, the impact of EMAP II overexpression
on cell cycle was explored. Progression from the G0 phase of cell
cycle was examined in chemically synchronized pEGFP-N3 and
pFEII-GFP cells. At 0 hour release, greater than 80% of both
clonal cell populations were in the G0 phase of cell cycle. Cells
progressed through cell cycle similarly in the early phases G1 and
S (Figure 1E, 13 hour). In contrast, cells overexpressing EMAP II
(pFEII-GFP, noted in red, Figure 1E) had a marked delay in G2M
progression that persisted for 2 hours noted between 14 and
15 hours (representative experiment, n=6 performed on different
occasions).
EMAP II over-expression increases cell migration
To assess potential effect of high intracellular EMAP II on cell
migration, in vitro scratch migration assay was performed using
A549 cells over-expressing EMAP II. As illustrated in Figure 2A &
2B, over-expression of EMAP II induced cell migration.
Quantitation of migratory cells by light microscope demonstrated
a marked increase in cell migration in EMAP II over-expressing
cells (50 percent increase) (Figure 2C, p,0.0001, unpaired
Student t-test, n=9 in triplicate performed on 3 different
occasions) as compared to control. To confirm that there no
cellular proliferation was occurring in the migrating cell
population, DAPI immunofluorescent staining was utilized. No
proliferation was noted in either cell population at the wound
margin (data not shown).
Nuclear/cytoplasmic partitioning of EMAP II in NIH 3T3
cells
As overexpression of EMAP II was noted to delay cellular
proliferation and cell cycle progression, we explored EMAP II
expression in the different phases of cell cycle. In chemically
synchronized NIH 3T3 cells, cell-cycle phases were examined for
EMAP II transcriptional and translational expression throughout
the different phases of the cell cycle (Figure 3A–D). EMAP II
protein expression increased 4-fold from G0 to the late G1 phase
of cell cycle and remained elevated through G2M (Figure 3A and
3B, p=0.02, ANOVA, n=4 on 4 different occasions). Impor-
tantly, at G2M cycle point EMAP II was phosphorylated (pEMAP
II) (Figure 3A, arrow pEMAP II). EMAP II RNA levels,
standardized to 18S, were transiently elevated 3 fold at late G1
prior to returning at the G1/S to levels (Figure 3C and 3D) (n=6,
performed on 6 different occasions).
To determine EMAP II cellular location during cell cycle
phases, chemical synchronization and immunofluorescence using
an N-terminal EMAP II antibody during G0, S, and G2M of cell
cycle was performed. EMAP II was identified in both cytoplasm
and nuclear locations, where its immunofluorescent expression
was predominately nuclear from G0 through S phase of cell cycle
(Figure 4A and 4C, respectively) followed by a reduction in
nuclear expression at G2M (Figure 4E) (n=duplicates performed
on 4 different occasions). Cytoplasmic and nuclear isolates from
synchronized NIH3T3 cells confirmed presence of EMAP II in
both fractions, but did not indicate significant nuclear–cytoplasmic
shifts in EMAP II during cell cycle (Figure 4G). Interestingly,
EMAP II’s nuclear location was found to be consistent with a
PSORT II analysis (http://psort.nibb.ac.jp/psort) indicating that
EMAP II contains three classical types of nuclear localizing
sequences (NLS) (Figure 4H). The first, pat4, is composed of 4
residue patterns of basic amino acids (K or R) and is located at the
aa 264–270 region of EMAP II. A second NLS, pat7, was noted by
a pattern starting with P that is subsequently followed within 3
residues by a basic segment containing 3 K/R residues out of 4.
This region is also located in the aa 264–270 region. Lastly, a
bipartite NLS containing 2 basic residues, 10-residue spacer, and a
second basic region consisting of at least 3 basic residues out of 5
were identified in region aa 121–137 of EMAP II. Utilizing
protein K and R compositions, one can predict EMAP II’s
subcompartmentalization. Computation of EMAP II’s K and R
composition predicts that 87% of EMAP II is localized to the
nucleus (Figure 4I).
EMAP II is phosphorylated at amino acid number 84,
threonine, by cdk1, and is compartmentalized in the
nucleus
As Cdk1 has a prominent role in controlling progression
through the G2M cell cycle phase, and since a Cdk1 binding
domain was identified in EMAP II’s N-terminal region (aa 84–87,
TPLH, Figure 5A), binding of Cdk1 to EMAP II was examined.
Immunoprecipitation with Cdk1 using whole cell lysates indicate
that EMAP II binds to Cdk1 during the G2M transition
(determined by FACs of cells simultaneously plated) (Figure 5B;
n=4 performed on 4 different occasions). Co-immunofluores-
cence of EMAP II and Cdk1 suggests that during G0 phase (Figure
S1A, S1B, S1C) EMAP II and Cdk1 are expressed in the
cytoplasm and nucleus with predominate nuclear expression by
both in S phase (Figure S1D, S1E, S1F). In contrast, during G2M,
EMAP II is predominately cytoplasmic (Figure S1G, S1I) with
Cdk1 being both nuclear and cytoplasmic (Figure S1H, S1I).
Phosphorylation of EMAP II at G2M suggests that it may be
interacting with one of the prominent kinases that has been
identified as facilitating the transition of cells into mitosis, Cdk1, a
serine/threonine kinase. Motif scanning (http://scansite.mit.edu)
of the EMAP II sequence identified two potential sites for Cdk1
phosphorylation, threonine at amino acid number 84, and serine
located at the 232 amino acid site (Figure 6A). Utilizing a
recombinant bacterial system three different EMAP II isoforms
[FL (full length) EMAP II, CT (C-terminal) EMAP II and NT (N-
EMAP II Is Phosphorylated by Cdk1
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ylation candidates. Electrophoresis analysis performed on isolates
gathered during the purification process indicated that the
recombinant his-tagged purified recombinant EMAP II protein
isoforms were soluble (Figure 6B). Cdk1 assay performed on
recombinant EMAP II isoforms suggest that FL-EMAP II and
Figure 1. EMAP II overexpression delays cell proliferation. Cell doubling, proliferation and progression through cell cycle were examined in
clonal A549 cell populations overexpressing either EMAP II (pFEII-GFP) or GFP (pEGFP-N3). Western analysis of cell lysates using either EMAP II (A) or
GFP (B) antibody confirmed expression. EMAP II overexpressing cells were found to have a marked delay in cell doubling (C, p,0.05), growth rate (D,
p,0.001), and a delay in exiting the G2M phase of cell cycle as noted at 14 and 15 hours post synchronized cell release (*, E) as compared to the
empty vector control (pEGFP-N3) (these experiments were performed a minimum of 4 times).
doi:10.1371/journal.pone.0033101.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33101Figure 2. Overexpression of EMAP II increases cell migration. Confluent cells were wounded using a rubber policeman, wounding site
marked, and examined for migration 15 hours post wounding. The black line represents the wounded margin. Cells overexpressing pFEII-GFP (B,C)
had a marked increase in migration as compared empty vector control (pEGFP-N3, A,C) (p,0.0001) (n=9 in triplicate performed on 3 different
occasions).
doi:10.1371/journal.pone.0033101.g002
Figure 3. EMAP II is phosphorylated at G2M phase of cell cycle. EMAP II translation and transcription were examined in chemically
synchronized cells throughout the phases of cell cycle. Western blot analysis indicated that upon exiting G0, EMAP II protein was increased
throughout cell cycle and was phosphorylated at G2M (A,B). EMAP II transcription was minimally impacted during the different phases of cell cycle
(C,D) (these experiments were performed a minimum of 4 times).
doi:10.1371/journal.pone.0033101.g003
EMAP II Is Phosphorylated by Cdk1
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Cdk1 indicating that the site of phosphorylation was located in the
N-terminal region of EMAP II, threonine at 84. Specificity of
Cdk1 phosphorylation was confirmed when FL-EMAP II and NT-
EMAP II were phosphorylated by Cdk1, but point mutations
introduced at the threonine 84 amino acid site to change the
threonine to alanine (FL-EMAP II TDAla) or asparagine (FL-
EMAP II TDAsn) were not phosphorylated by Cdk1 (Figure 6D)
(n=9 performed on 3 different occasions). These data suggest that
EMAP II binds to Cdk1 and is phosphorylated at the threonine
aa84 by Cdk1 during G2M of cell cycle. Using an pThr84-EMAP
II antibody, we examined the distribution of phospo-EMAP II
during cell cycle. In contrast to our previous analysis of cell lysate,
we determined that phospho-EMAP II is predominately nuclear
while unphosphorylated EMAP II is cytoplasmic (Figure 7).
Discussion
Intracellular EMAP II expression is increased during fetal
development at epithelial/mesenchymal boundaries [19,21] and
in pathophysiologic fibroproliferative processes such as the distal
alveoli of BPD [22], emphysema [23], and the scar tissue of
myocardial ischemia [24]; the functional role of intracellular
EMAP II, however, is poorly understood. EMAP II’s pathophys-
iologic distribution raised the possibility that EMAP II may have a
role in cellular proliferation. Overexpression of intracellular
EMAP II delayed proliferation of epithelial cells, doubling, and
transition through the G2M phase of the cell cycle without
inducing cellular apoptosis, while increasing cell migration. Based
on a recent study, some anti-angiogenic proteins cleaved from
larger precursor proteins can demonstrate separate and indepen-
dent intracellular functions that antagonize the cleaved anti-
angiogenic form [25]. For example, the anti-angiogenic protein
endostatin is cleaved from the larger secreted extracellular matrix
protein Collagen XVIII. Whereas endostatin inhibits endothelial
cell proliferation, migration and induces apoptosis, collagen XVIII
positively regulates the extracellular matrix-dependent motility
and morphogenesis of endothelial cells. This dichotomous
coupling of a vascular agonist and antagonist, with its dependency
on the proteolytic cleavage of one protein, suggests that there is an
autoregulatory feedback loop between the two isoforms [25].
In addition, examination of EMAP II expression and distribu-
tion during the cell cycle progression revealed an elevation in
EMAP II protein during G1-G2M stages of cell cycle with EMAP
II phosphorylation, nuclear and cytoplasmic distribution, binding
and phosphorylation to Cdk1, and phosphorylated EMAP II being
confined to the nuclear isolates. These findings indicate that
EMAP II has an intracellular role affecting cellular proliferation
and migration, i.e. acting as an agonist to which its extracellular
role carries an anti-angiogenic antagonistic function.
Cell cycle progression is controlled by a series of carefully
regulated signals that involve protein phosphorylation. For
example, the regulatory activity of cdc2/Cdk1 (cyclin dependent
kinase 1), a primary determinant of mitosis, is dependent on its
phosphorylation state. Inhibitory phosphorylation of Cdk1
restrains it to an inactive state. Once dephosphorylated, Cdk1 is
activated to facilitate the mitosis transition through reorganization
of cellular structures, chromosome condensation, disassembly of
the nuclear envelope, and assembly of the mitotic spindle [26];
[27]. Inhibition of Cdk1 dephosphorylation maintains its inactive
Figure 4. EMAP II undergoes nuclear/cytoplasmic partitioning during cell cycle. EMAP II distribution was assessed in chemically
synchronized cell populations. Immunofluoresence indicated EMAP II expression is predominately nuclear in G0 (A,B) and S (C,D) phase, whereas in
G2M (E/F) nuclear EMAP II is reduced. Western blot analysis (G) of isolated nuclear and cytoplasmic fractions indicates EMAP II expression is
maintained in both compartments through out cell cycle (these experiments were performed 4 times). PSORT II analysis determined there were three
classical types of nuclear localizing sequences (NLS): pat4, pat7, and a bipartite NLS (H). Proteins K and R composition predicts that 87% of EMAP II is
subcompartmentalization to the nucleus EMAP II’s (I). Magnification in A–F: 10006.
doi:10.1371/journal.pone.0033101.g004
EMAP II Is Phosphorylated by Cdk1
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[28,29]. We determined that EMAP II complexes to Cdk1 during
the G2M phase and is phosphorylated by Cdk1. Furthermore,
phosphorylated EMAP II was confined to the nucleus and its
overexpression delayed G2M progression. These findings raise
several possible mechanisms. In cell cycle progression EMAP II
may either simply carry the phosphate that allows retention of
active Cdk1 longer, or be activated to partake in cell cycle
regulation itself. Dissecting out the mechanism of EMAP II-related
delay of G2M progression is the primary focus of our ongoing
studies.
Following tissue injury, remodeling occurs that is mediated
through inflammatory, trans-differentiation, and apoptotic mecha-
nisms. In contrast to CT-EMAP II’s well-documented extracellular
pro-inflammatory roles [30,31,32,33], the functional role of intracel-
lular EMAP II in pathophysiologic states has remained poorly
understood. Intracellular expression of EMAP II is increased in
fibroproliferative regions of disease states such as the BPD dysplastic
alveoli [22] or the wound region of an infarcted myocardium [24]
suggesting a potential physiologic role in wound repair. While
apoptosis is a hallmark of many disease process and tissue repair,
intracellular overexpression of EMAP II was not found to increase
apoptosis via PARP-1 cleavage or JNK pathway. One previous study
suggests that intracellular EMAP II is not pro-inflammatory, but
rather suppressive of fibroblast proliferation in wound healing studies
in mice with depletion of EMAP II/p43 expression using gene
disruption [31]. Their findings are consistent with our findings that
EMAP II has a specific regulatory role in cell proliferation. However,
wound healing requires reciprocal events involving cellular migration
and proliferation. Initial stages of wound healing involve the
recruitment of immune cells and cellular migration, while macro-
phages contribute to later stages of reconstruction through the
secretion of factors that regulate epithelial and fibroblast cellular
migration and proliferation. Previous studies indicate that EMAP II
expression is markedly increased in the wounded region [24] with
migrating macrophages also strongly expressing EMAP II. In our
studies EMAP II overexpression significantly increased cellular
migration while suppressing proliferation suggesting that EMAP II
may have an impact on the microenvironment and cellular
components that restore tissue homeostasis and balance the tissues
repair response. Whether EMAP II’s ability to delay cellular
proliferation while increasing cellular migration impacts trans-
differentiation during tissue remodeling is an area of ongoing
research within our laboratory.
In conclusion, our studies show for the first time a functional
role for intracellular EMAP II where EMAP II is phosphorylated
by Cdk1 in the nuclear compartment and influences cellular
proliferation and migration in a reciprocal fashion. Furthermore,
these findings suggest that the intracellular function of EMAP II
possibly antagonizes its extracellular anti-angiogenic functions
during fetal development [19,21], pulmonary disease progression
[22,23,34], and wound healing [24]. These findings broaden our
Figure 5. EMAP II contains a Cdk1 binding site and immuno-precipitates with Cdk1 during S and G2M phases of cell cycle. A Cdk1
binding domain, TPLH, was identified in EMAP II’s N-terminal region at aa 84–87 (A). Immunoprecipitation using Cdk1 determined that EMAP II binds
to Cdk1 during S and G2M phase of cell cycle (B) (these experiments were performed 4 times).
doi:10.1371/journal.pone.0033101.g005
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EMAP II in development and wound healing processes.
Materials and Methods
Cells
NIH3T3 fibroblasts and carcinomic human alveolar basal
epithelial cell line A549 cells, purchased from ATCC (Mana-
ssas,VA), were grown in DMEM, 10% CBS (calf bovine serum,
ATCC, Manassas,VA) 1% Penicillin/Streptomycin (Sigma, St.
Louis, MO) and 5% CO2. Cells were passaged every 3–4 days
utilizing trypsinization techniques.
Construction of human EMAP II-GFP fusion plasmid,
pFEII-GFP
The open reading frame of full-length EMAP II was amplified
using a high fidelity PCR kit (Sigma Aldrich, St. Louis, MO) from
previously constructed plasmid pET28a FEII [34]. The PCR
product was digested with Xho I plus Hind III and inserted into
vector pEGFP-N3 cut with Xho I plus Hind III. Plasmid accuracy
was verified with restriction digestion and DNA sequencing.
Establishment of A549 Stable clones
A549 cells were maintained in our lab and cultured in DMEM
containing10%fetalbovineserumat37uCwi t h5%CO 2.A5 49ce ll s
were transfected with plasmid pEGFP-N3 and pFEII-GFP using
TransIT LT1 (Mirus Bio, Madison, WI) transfection reagent. After
24 hours,A549cellsweresplitat1:20into10 cmdishes.A549stable
clone cells were selected using 900 mcg/ml of G-418 for 2–3 weeks.
GFP-positive cells were picked for further analysis under fluores-
cence microscope. Overexpression of GFP and EMAPII GFP fusion
protein were confirmed using Western Blotting analysis.
Cell growth curves, Proliferation and Migration studies
Stably transfected A549 cell lines, A549 vector control (pEGFP-
N3) and overexpressing EMAP II (pFEII-GFP) were plated in
duplicate at 0.25610
6 cells/ml, and allowed to grow in G418
800 mg/ml (Invitrogen, Carlsbad, CA). Cells were collected and
counted on days 1–5. For proliferation assays, pEGFP-N3 and
pFEII-GFP cells were plated in 6 wells of a 96-well plate at a
concentration of 1000 cells/well in G418 800 mg/ml. Cells were
allowed to grow for 5 days. Each day 1–5, 10 ml of proliferation
reagent WST-1 (Roche, Indianapolis, IN)was added to eachof the 6
wells. Plates were placed in a 5% CO2,3 7 uC incubator for one hour
and then were read by POLARstar Omega - Fluorescence
Polarization microplate reader (BMG Labtech, Cary, NC) at
450 nmtoassesscellproliferation.Migrationstudieswereperformed
in 6 well plates. Once cells reached confluence, a wound was created
using a sterile rubber policeman. Sites of wounding were marked at
time of initiation and migration was assessed 14–16 hours post
wounding. Following image capturing using light microscopy, cells
were fixed with paraformaldehyde and stained with the nuclear stain
DAPI (49,6-Diamidino-2-phenyindole 5 mg/ml at 1:1,000 dilution,
Sigma Aldrich, St. Louis, MO) to assess for cellular proliferation. A
blinded observer performed migration determined as the number of
cells that migrated past the wound edge.
Chemical synchronization
Asynchronized cells were grown in 10% fetal bovine serum
(FBS) at 50% confluence prior to starvation conditions (0.5% FBS)
Figure 6. Cdk1 phosphorylates EMAP II at amino acid 84, threonine. Two potential Cdk1 phosphorylation sites were identified, aa 84
threonine, and serine at aa 232 (A). Using recombinant EMAP II protein isolates (B) in a Cdk1 assay, only the N-terminal and full-length EMAP II were
phosphorylated by Cdk1 (C). Point mutation within the threonine (aa 84) to change the amino acid to either asparagine or alanine eliminated Cdk1
phosphorylation, thus confirming that the 84 aa threonine was the site of Cdk1 phosphorylation of EMAP II (D) (these experiments were performed 3
times).
doi:10.1371/journal.pone.0033101.g006
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400 mM mimosine for 24 hours. Exposure of cells to twenty-four
hour of Aphidicolin 2 mg/ml placed the cells at the G1/S junction.
S phase was achieved using a G1/S junction delay (Aphidicolin)
plus 4 hours release (confirmed with FACS analysis). The G2/M
boundary was reached using nocodazole 100 ng/ml for 24 hours.
For evaluation of cell cycle progression, stably transfected A549
pEGFP-N3 and pFEII-GFP clonal were allowed to grow to 50%
confluence and switched to starving conditions (no FBS) for
48 hrs. Cell arrest was accomplished by adding 8 mg/ml
aphidicolin (Sigma Aldrich, St. Louis, MO) in DMEM with FBS
for 24 hrs. To see differences in how cells enter/leave G2,
aphidicolin treated medium was removed and cells were collected
for FACS analysis at 0,12,13,14,15,16,17 hours following release.
FACs analysis
Following trypsinization, cells were centrifuged, washed with
PBS, and fixed while vortexing with 70% ethanol. Fixed cells were
washed with PBS and treated with RNAse 20 mg/ml (Sigma
Aldrich, St. Louis, MO) at 37uC for 1 hour. Cells were stained
with propidium iodine (PI) (20 mg/ml, Sigma Aldrich, St. Louis,
MO). Some cells were preincubated with annexin V-FITC
followed by PI prior to FACs analysis. Fluorescence of cells was
measured at 488 nm by FACS Calibur (Becton Dickinson,
Franklin Lakes, NJ) at the Flow Cytometry Core Facility at
UTSW Medical Center.
Recombinant protein
Recombinant EMAP II protein was obtained as previously
described [34]. The cDNA of EMAP II was cloned from RT-PCR
products of U937 cells total RNA based on primers obtained from
gene bank (accession #10119) into TA vector (Invitrogen,
Carlsbad, CA). Clonal confirmation was provided by sequence
analysis, after which the cDNA was inserted into PET28a, 66his-
tag containing plasmid, protein purified as previously described
[34]. Point mutations were made in EMAP II at amino acid
position 84 where the threonine was mutated to an alanine or
asparagines using QuikChange Site-Directed Mutagenesis Kit
(Stratagene, Santa Clara, CA) and confirmed by sequence
analysis.
Western Blot Analysis
A549 cells were harvested and washed with ice-cold PBS twice.
Cell pellets were resuspended in lysis buffer, protein concentration
was measured using BCA method (Biorad, Hercules, CA), and
equal amounts of protein were subjected to SDS-PAGE and
transferred onto PVDF membrane. After blocking membranes
were probed with the appropriate primary antibody [EMAP II
[34], pEMAP II (YenZym Antibodies, San Francisco, CA), Cdk1
(Abcam, Cambridge, MA), Lamin B (Abcam, Cambridge, MA),
JNK (Santa Cruz Biotechnologies, Santa Cruz, CA), poly (ADP-
ribose) polymerase-1 (PARP-1) (Cell SignalingTechnology, Bev-
erly, MA), GAPDH (Sigma Aldrich, St. Louis, CA)]. Specific
Figure 7. Phosphorylated EMAP II is predominately localized in the nuclear fraction. A phosphorylated pThr84-EMAP II antibody was
obtained (A) and phospo-EMAP II was examined in nuclear and cytoplasmic fractions during cell cycle. Phospho-EMAP II was found in the nuclear
fraction G0-S phase of cell cycle with only the phosphorylated form found in the cytoplasm during G2M. Unphosphorylated EMAP II (capable of
recognizing unphosphorylated and phosphorylated EMAP II) was confined to the cytoplasm as only a single band corresponding with the
phosphorylated form was found in the nuclear isolates (B). Lamin B nuclear envelope confirmed nuclear isolate specificity (these experiments were
performed a minimum of 4 times).
doi:10.1371/journal.pone.0033101.g007
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Rockford, IL) and XAR-5 film (Eastman Kodak, Rochester, NY).
Quantitative analysis was accomplished using NIH Image and
samples were normalized for background. In some cases, following
lysis of cells, equal amounts of protein were added to tubes
containing the antibody for immunoprecipitation (IP), incubated,
followed by the addition of washed Protein A beads. Beads were
washed, electrophoresed, and processed as described above.
Immunoprecipitation was performed on 200 mg of total protein
and each experiment contained internal controls (no protein A
beads, no primary antibody, and no lysate). For some studies,
nuclear and cytoplasmic fractions were isolated using NE-PER
Nuclear and Cytoplasmic Extraction Kit (Pierce) as per manufac-
ture protocol prior to subjecting samples to electrophoresis.
Nuclear and cytoplasmic specificity was confirmed using the
Lamin B nuclear envelope marker. pThr84-EMAP II antibody
was created using a synthesized phosphorylated EMAP II peptide
and purified using an affinity matrix purification (YenZym
Antibodies, San Francisco, CA).
Kinase assay
Target proteins were incubated with 15 mci c - 32P dATP,
1 mM ATP (100 mm/reaction) and 4 units Cdk1 for 1 hour at 30u
Celsius. Samples were then electrophoresed on a 12% Tris-
Glycine gel, transferred to a PVDF membrane and exposed to an
autoradiography overnight. Concomitant controls were performed
without kinase as a substrate [35].
Immunohistochemistry analysis
Cells plated on plastic chamber slides were synchronized as
described above. Cells were then washed in PBS prior to fixation
with 4% paraformaldehyde for 15 min. Following permeabiliza-
tion with 0.1% Triton-X, cells were washed with PBS, blocked
using CSA (Zymed, San Francisco, CA) and exposed to a C-
terminal EMAP II primary antibody for 1 hour as previously
described [20]. Following washing with PBS, cells were exposed to
the appropriate secondary fluorescent antibody (Chemicon,
Temecula, CA), incubated with membrane permeable DAPI
(49,6-Diamidino-2-phenyindole 5 mg/ml at 1:1,000 dilution,
Sigma Aldrich, St. Louis, MO), and mounted. In some cases,
co-localization was performed using the C-terminal EMAP II
antibody followed by exposure to the appropriate secondary
antibody. This was followed by exposure to a Cdk1 antibody and
then appropriate secondary antibody. The signal was viewed by
fluorescent microscopy at the appropriate wavelength for the
secondary antibody on a BX50 Olympus microscope, and images
were obtained using an Olympus DP70 digital camera.
Statistics
Statistical analysis was performed using Student’s t-test and one
way ANOVA on software Statview for Macintosh (SAS Institute,
Gary, NC) and PRISM 4.0 for Macintosh (GraphPad Software,
Inc., San Diego, CA). P-values of ,0.05 were considered to
represent statistically significant differences.
Supporting Information
Figure S1 EMAP II and Cdk1 co-localize throughout cell
cycle. Distribution of EMAP II and Cdk1 were examined
throughout cell cycle using co-immunofluorescence. During G0
(A–C) EMAP II (A) and Cdk1 (B) were expressed in the cytoplasm
and nucleus with a transition to a predominate nuclear expression
in S phase (D–F). In contrast, during G2M EMAP II is
predominately cytoplasmic (G,I) with Cdk1 being both nuclear
and cytoplasmic (H,I). Magnification: 6006 (these experiments
were performed a minimum of 3 times).
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